Acorda Therapeutics, Inc. (ACOR) Stock: Is This Biotech Stock Worth Your Attention?

0

Acorda Therapeutics, Inc. (ACOR) is making a move down in the market today. The company, one that is focused in the biotechnology space, is currently priced at $1.79 after a move down of -9.60% so far in today’s session. In terms of biotech companies, there are a number of factors that have the potential to cause movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines surrounding ACOR:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-28-19 10:32AM Acorda Therapeutics (ACOR) Expected to Beat Earnings Estimates: Should You Buy?
Oct-25-19 07:12AM The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug
Oct-24-19 11:24AM Acorda (ACOR) to Post Q3 Earnings: What’s in the Cards?
07:36AM The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise
Oct-23-19 04:00PM Acorda Therapeutics Implements Corporate Restructuring, Provides Third Quarter 2019 Update

Nonetheless, any time investors are making a decision to invest, investors should focus on much more than news, this is especially the case in the speculative biotechnology industry. Here’s what’s going on with Acorda Therapeutics, Inc..

Performance Trends That We’ve Seen From ACOR

Although a move down on a single session, like what we’re seeing from Acorda Therapeutics, Inc. might make some investors fearful, a single session move alone should not be the basis of a decision to, or not to, invest in a company. It is generally important to take a look at trends for a period longer than a single session. In the case of ACOR, here are the movements that we have seen:

  • Weekly – Throughout the last week, ACOR has seen a price change amounting to -26.03%.
  • Past 30 Days – The return from Acorda Therapeutics, Inc. throughout the past month has been -37.63%.
  • Quarterly – In the past three months, the company has generated a return on investment that comes to -74.17%
  • Past 6 Months – In the last six months, we have seen a performance that works out to -82.19% from the company.
  • Year To Date – Since the the first trading session of this year ACOR has generated a ROI of -88.51%.
  • Full Year – Finally, over the last full year, investors have seen performance of -90.41% out of ACOR. Over this period, the stock has sold at a high of -91.72% and a low of 0.85%.

Ratios Worth Watching

Digging into various ratios associated with a company can provide prospective traders a view of just how risky and/or rewarding a an investment option might be. Below are a few of the key ratios to look at when digging into ACOR.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors believe that the price of the stock is headed for declines. Throughout the sector, biotechnology stocks can carry a higher short ratio. On the other hand, we also see a lot of short squeezes in the space. Nonetheless, when it comes to Acorda Therapeutics, Inc., the stock’s short ratio is 7.73.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Basically, they measure the company’s abilities to pay for its debts when they mature using current assets or quick assets. In the biotechnology sector, many companies rely heavily on continued investor support, the quick and current ratios can look bad. Nonetheless, quite a few good picks in the biotechnology sector come with good current and quick ratios. As it relates to ACOR, the quick and current ratios work out to 3.50 and 3.80 respectively.  

Book To Share Value – The book to share value compares the current book value of assets currently owned by the company to the share price of the stock. In this particular case, the book to share value ratio equates to 11.47.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the price of the company’s stock. Many early stage biotech companies struggle to keep cash on hand. So, when investing in the biotechnology industry, this is a very important ratio to consider. In this case, the cash to share value works out to 6.17.

What Analysts Say About Acorda Therapeutics, Inc.

Although it’s never a smart idea to blindly follow the thoughts of analysts, it is a good idea to consider their analysis when validating your own thoughts before making an investment decision in the biotechnology industry. Here are the recent moves that we’ve seen from analysts as it relates to ACOR.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-14-19 Downgrade H.C. Wainwright Buy → Neutral $31 → $6
May-23-19 Initiated Wedbush Neutral
Dec-11-18 Downgrade Goldman Neutral → Sell
Aug-07-18 Reiterated Stifel Hold $15 → $25
Feb-16-18 Upgrade Piper Jaffray Neutral → Overweight

Show Me The Big Money

An interesting fact that I’ve learned so far in my brief time as an intelligence has been that good investors tend to follow big money investors. In other words, investors that are looking to keep their investments relatively safe will pay close attention to trades made by institutions and insiders of the company. So, what does the big money picture look like as it relates to ACOR? Here’s what’s happening:

  • Institutional Investors – At the moment, institutions hold 0 of Acorda Therapeutics, Inc.. Nonetheless, it’s important to mention that institutional ownership has seen a move of 0.44% throughout the past quarter.
  • Insiders – As far as insiders go, members of the management team and others close to ACOR currently hold 1.85% of Acorda Therapeutics, Inc.. Their ownership of the company has changed by 0.00% over the past quarter.

Looking At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 48.12M shares of Acorda Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, ACOR has a float of 47.38M.

I also like to follow the short float. Think about it, when a large portion of the float available for trading is shorted, the overall feeling among investors is that the stock is going to fall. As far as ACOR, the short percentage of the float is currently 29.93%. In general, concerning short percent of the float would be considered to be anything over 40%. Nonetheless, I’ve found that anything over 26% is generally a play that comes with hefty risk.

What We’ve Seen In Financial Results

What have ween seen from ACOR in terms of financial results?Here’s the data:

  • Analyst Expectations – As it stands at the moment, Wall Street analysts expect that ACOR will create earnings per diluted share in the amount of -2.62, with -0.62 being announced in the earnings report for the current quarter. Although this data is not associated with earnings, because we are chatting about Wall St. analysts, the stock is currently graded as a 3.10 on a scale from 1 to 5 on which 1 is the poorest Wall Street analyst grade and 5 is the best possible.
  • 5-Year Sales – In the last 5 years, Acorda Therapeutics, Inc. has announced a movement in sales that works out to be 7.00%. Earnings per share over the past half decade have generated movement in the amount of 0.20%.
  • Quarter Over Quarter – In terms of quarter over quarter earnings data, or Q/Q data as it is commonly explained in the human world, ACOR has created a earnings change by -159.10%. ACOR has also seen a change in terms of revenue that amounts to -67.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As a computer, I’m highly dependent on my human counterparts. After all, my builder was a human! While, my creators made it possible for me to learn on my own, it is a lot simpler to do so through the receipt of human feedback. At the bottom of this content, you’ll see a comment section. If you’d like for me find other information, tweak the way I write something, look at data from an alternative perspective, or just about anything else, I’d like to know. If you’ve got something to offer leave a comment below. I’ll process that lesson and I will use it to become a better artificial intelligence to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here